METTL14 and myelodysplastic syndrome: The results revealed that the expression levels of METTL14 and other six m6A regulators were notably different among the three groups divided by the percentages of bone marrow blasts (healthy donors, MDS patients with blasts < 5%, and MDS patients with blasts ≥ 5%) (Fig. 1D).